📊 VCNX Key Takeaways
Is Vaccinex, Inc.. (VCNX) a Good Investment?
Vaccinex faces imminent financial distress with negative stockholders' equity of -$2.5M and critical liquidity (0.50x current ratio), providing only ~40 days of cash runway against $16.2M annual operating burn. The company's $601K annual revenue cannot support $18.7M operating losses, indicating a fundamentally broken business model with no viable path to profitability.
Why Buy Vaccinex, Inc.. Stock? VCNX Key Strengths
- No significant long-term debt burden limiting financial flexibility
- Modest revenue growth of 5.4% YoY demonstrates some market traction
- EPS improving 79.7% YoY shows management focus on cost control
VCNX Stock Risks: Vaccinex, Inc.. Investment Risks
- Technically insolvent with negative equity of -$2.5M; unable to cover total liabilities with assets
- Liquidity crisis: 0.50x current ratio with approximately 40 days of cash runway at current $16.2M annual burn rate
- Extreme operating losses of -$18.7M on $601K revenue (-3100% net margin) demonstrate economically non-viable business model
Key Metrics to Watch
- Monthly cash burn rate and path to positive cash flow or external funding
- Gross margin and unit economics if revenue scales materially
- Quarterly revenue trajectory and customer concentration risk
Vaccinex, Inc.. (VCNX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
VCNX Profit Margin, ROE & Profitability Analysis
VCNX vs Healthcare Sector: How Vaccinex, Inc.. Compares
How Vaccinex, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Vaccinex, Inc.. Stock Overvalued? VCNX Valuation Analysis 2026
Based on fundamental analysis, Vaccinex, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Vaccinex, Inc.. Balance Sheet: VCNX Debt, Cash & Liquidity
VCNX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Vaccinex, Inc..'s revenue has grown significantly by 15% over the 5-year period, indicating strong business expansion. The most recent EPS of $-43.68 indicates the company is currently unprofitable.
VCNX Revenue Growth, EPS Growth & YoY Performance
VCNX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $20.0K | -$4.9M | $-2.83 |
| Q2 2024 | $232.0K | -$5.6M | $-3.10 |
| Q1 2024 | $104.0K | -$3.9M | $-2.94 |
| Q3 2023 | $20.0K | -$4.8M | $-1.09 |
| Q2 2023 | $550.0K | -$5.4M | $-0.12 |
| Q1 2023 | $550.0K | N/A | $-0.10 |
| Q3 2022 | $50.0K | -$4.8M | $-0.11 |
| Q2 2022 | $850.0K | -$5.4M | $-0.13 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Vaccinex, Inc.. Dividends, Buybacks & Capital Allocation
VCNX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Vaccinex, Inc.. (CIK: 0001205922)
📋 Recent SEC Filings
❓ Frequently Asked Questions about VCNX
What is the AI rating for VCNX?
Vaccinex, Inc.. (VCNX) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are VCNX's key strengths?
Claude: No significant long-term debt burden limiting financial flexibility. Modest revenue growth of 5.4% YoY demonstrates some market traction.
What are the risks of investing in VCNX?
Claude: Technically insolvent with negative equity of -$2.5M; unable to cover total liabilities with assets. Liquidity crisis: 0.50x current ratio with approximately 40 days of cash runway at current $16.2M annual burn rate.
What is VCNX's revenue and growth?
Vaccinex, Inc.. reported revenue of $601.0K.
Does VCNX pay dividends?
Vaccinex, Inc.. does not currently pay dividends.
Where can I find VCNX SEC filings?
Official SEC filings for Vaccinex, Inc.. (CIK: 0001205922) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is VCNX's EPS?
Vaccinex, Inc.. has a diluted EPS of $-8.88.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is VCNX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Vaccinex, Inc.. has a STRONG SELL rating with 95% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is VCNX stock overvalued or undervalued?
Valuation metrics for VCNX: ROE of N/A (sector avg: 15%), net margin of -3,100.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy VCNX stock in 2026?
Our dual AI analysis gives Vaccinex, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is VCNX's free cash flow?
Vaccinex, Inc..'s operating cash flow is $-16.2M, with capital expenditures of $22.0K. FCF margin is -2,696.8%.
How does VCNX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -3,100.5% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.50 (avg: 2).